Brad S. Kahl, MD
Ibrutinib (Imbruvica) has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma (MCL) since 2013, and long-term follow-up data for the BTK inhibitor continue to demonstrate its clinical activity.
Kahl, a professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discussed the latest data for ibrutinib and highlighted emerging treatments in MCL.
OncLive: Please discuss the evolving treatment options for patients with MCL.
Historically, there were not great options for relapsed/refractory MCL. We had conventional chemotherapy, which worked unsatisfactorily. We had bortezomib (Velcade), which had a relatively low overall response rate and short duration of response. We have had lenalidomide (Revlimid), which has a low response rate but can have durable responses for patients with relapsed MCL. When we were finally introduced to BTK inhibition, first with ibrutinib, we were happy to see higher response rates in the 60% to 70% range, along with better durability, with responses lasting an average of 18 months.
... to read the full story